Protease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy

Cited 83 time in webofscience Cited 0 time in scopus
  • Hit : 705
  • Download : 0
DC FieldValueLanguage
dc.contributor.authorYoo, Jisangko
dc.contributor.authorRejinold, N. Sanojko
dc.contributor.authorLee, DaeYongko
dc.contributor.authorJon, Sangyongko
dc.contributor.authorKim, Yeu-Chunko
dc.date.accessioned2017-11-08T02:21:23Z-
dc.date.available2017-11-08T02:21:23Z-
dc.date.created2017-10-23-
dc.date.created2017-10-23-
dc.date.issued2017-10-
dc.identifier.citationJOURNAL OF CONTROLLED RELEASE, v.264, pp.89 - 101-
dc.identifier.issn0168-3659-
dc.identifier.urihttp://hdl.handle.net/10203/226704-
dc.description.abstractReactive oxygen species (ROS)- or protease-responsive materials have been utilized as carriers in cancer therapies because ROS and specific proteases are overproduced in cancer cells. Methionine-based polypeptides containing a thioether group are promising candidates due to their ROS-responsiveness which provides a phase transition. Herein, we developed protease-activatable cell-penetrating peptide containing a ROS-responsive methionine, a cell permeable lysine chain, and a matrix metalloproteinase (MMP)-cleavable linker. We designed a poly(L-methionine-block-L-lysine)-PLGLAG-PEG (MLMP) and doxorubicin (DOX) was loaded into the micelle core. The MLMP exhibited MMP-sensitive cleavage and ROS-induced DOX release. Moreover, we confirmed efficient DOX delivery into cancer cells and induction of the apoptotic capability in vitro. In a bio-distribution study, IR-780 dye encapsulated MLMP showed superior tumor targetability with long retention. Furthermore, MLMP (DOX) exhibited outstanding tumor inhibition capability with non-toxicity compared to free DOX, indicating that dual stimuli-MLMP has great potential as an anticancer drug delivery platform.-
dc.languageEnglish-
dc.publisherELSEVIER SCIENCE BV-
dc.subjectGENE DELIVERY-
dc.subjectOXIDATIVE STRESS-
dc.subjectIN-VIVO-
dc.subjectINTRACELLULAR DELIVERY-
dc.subjectPCL NANOPARTICLES-
dc.subjectEFFICIENT-
dc.subjectMICELLES-
dc.subjectCONJUGATE-
dc.subjectPLATFORM-
dc.subjectRELEASE-
dc.titleProtease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy-
dc.typeArticle-
dc.identifier.wosid000412177500009-
dc.identifier.scopusid2-s2.0-85028033940-
dc.type.rimsART-
dc.citation.volume264-
dc.citation.beginningpage89-
dc.citation.endingpage101-
dc.citation.publicationnameJOURNAL OF CONTROLLED RELEASE-
dc.identifier.doi10.1016/j.jconrel.2017.08.026-
dc.contributor.localauthorJon, Sangyong-
dc.contributor.localauthorKim, Yeu-Chun-
dc.description.isOpenAccessN-
dc.type.journalArticleArticle-
dc.subject.keywordAuthorReactive oxygen species-
dc.subject.keywordAuthorActivatable cell-penetrating peptide-
dc.subject.keywordAuthorDoxorubicin-
dc.subject.keywordAuthorMatrix metalloproteinase-
dc.subject.keywordAuthorAnticancer drug delivery-
dc.subject.keywordPlusGENE DELIVERY-
dc.subject.keywordPlusOXIDATIVE STRESS-
dc.subject.keywordPlusIN-VIVO-
dc.subject.keywordPlusINTRACELLULAR DELIVERY-
dc.subject.keywordPlusPCL NANOPARTICLES-
dc.subject.keywordPlusEFFICIENT-
dc.subject.keywordPlusMICELLES-
dc.subject.keywordPlusCONJUGATE-
dc.subject.keywordPlusPLATFORM-
dc.subject.keywordPlusRELEASE-
Appears in Collection
BS-Journal Papers(저널논문)CBE-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 83 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0